surmount-1 trial tirzepatide obesity without diabetes weight loss SURMOUNT 1 // Three-Year Obesty & Prevention Outcomes tirzepatide trial obesity without diabetes

They found that both methods effectively reduced body weight, with participants losing around 5.5 to 6.5 kilograms (roughly 12 to 14 pounds) after six months

Abstract Background Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA)

Turton MD, OShea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al

Strength training supports metabolism and mobility

At this time our providers believe that the use of this medication works best in conjuncture with added B12

The Most Concerning Long-Term Risks of GLP-1 Drugs Below are the strongest areas of concern based on clinical observations, case reports, patient outcomes, and developing research